The startup operates a biotherapeutics platform that utilizes protein engineering to modulate the activity of immunotherapies, aiming to minimize the side effects associated with cancer treatments. By enhancing drug efficacy and safety, the company provides healthcare providers with improved therapeutic options for patients undergoing cancer therapy.
Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic immunotherapies often induce off-target effects, leading to significant side effects and limiting the dosage and efficacy of cancer treatments. The lack of precise control over drug activity can compromise patient safety and therapeutic outcomes.
Solution
Troya Therapeutics is developing a biotherapeutics platform that leverages protein engineering to enhance the safety and potency of immunotherapies. Their approach utilizes a novel, natural protein scaffold that selectively activates drugs at the disease site, minimizing exposure to healthy tissues. By precisely controlling drug activity, Troya aims to improve therapeutic efficacy while reducing adverse side effects associated with systemic administration. This targeted activation strategy offers the potential for safer and more effective cancer treatments.
Target Audience
The primary target audience includes healthcare providers and pharmaceutical companies focused on developing and delivering safer, more effective cancer therapies.
Features
- Protein engineering platform for modulating the activity of biologic drugs
- Novel protein scaffold for targeted drug activation at the disease site
- Enhanced drug potency and reduced off-target effects
- Improved therapeutic index for immunotherapies